Market openADR
Novo Nordisk/$NVO
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Novo Nordisk
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Ticker
$NVO
Sector
Health Care
Trading on
NYSE
Industry
Pharmaceuticals
Headquarters
Bagsvaerd, Denmark
Employees
69,260
Website
Novo Nordisk Metrics
BasicAdvanced
$521B
40.38
$2.92
0.15
$1.03
0.61%
Price and volume
Market cap
$521B
Beta
0.15
52-week high
$148.15
52-week low
$92.94
Average daily volume
4.1M
Dividend rate
$1.03
Financial strength
Current ratio
0.945
Quick ratio
0.739
Long term debt to equity
45.865
Total debt to equity
50.71
Dividend payout ratio (TTM)
46.71%
Interest coverage (TTM)
1,769.75%
Management effectiveness
Return on assets (TTM)
22.80%
Return on equity (TTM)
88.57%
Valuation
Price to earnings (TTM)
40.381
Price to revenue (TTM)
14.03
Price to book
31.98
Price to tangible book (TTM)
63.1
Price to free cash flow (TTM)
54.821
Dividend yield (TTM)
0.87%
Forward dividend yield
0.61%
Growth
Revenue change (TTM)
28.15%
Earnings per share change (TTM)
34.93%
3-year revenue growth (CAGR)
25.70%
3-year earnings per share growth (CAGR)
28.06%
3-year dividend per share growth (CAGR)
28.42%
What the Analysts think about Novo Nordisk
Analyst Ratings
Majority rating from 10 analysts.
Novo Nordisk Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
kr 65B
-0.78%
Net income
kr 25B
15.68%
Profit margin
38.87%
16.59%
Novo Nordisk Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
kr 4.32
kr 5.00
kr 4.91
kr 5.68
-
Expected
kr 4.41
kr 5.00
kr 4.48
kr 5.14
kr 5.53
Surprise
2.09%
0.09%
9.55%
10.57%
-
Novo Nordisk News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Novo Nordisk stock?
Novo Nordisk (NVO) has a market cap of $521B as of April 24, 2025.
What is the P/E ratio for Novo Nordisk stock?
The price to earnings (P/E) ratio for Novo Nordisk (NVO) stock is 40.38 as of April 24, 2025.
Does Novo Nordisk stock pay dividends?
Yes, the Novo Nordisk (NVO) stock pays dividends to shareholders. As of April 24, 2025, the dividend rate is $1.02575 and the yield is 0.61%. Novo Nordisk has a payout ratio of 46.71% on a trailing twelve-month basis.
When is the next Novo Nordisk dividend payment date?
The next Novo Nordisk (NVO) dividend payment date is unconfirmed.
What is the beta indicator for Novo Nordisk?
Novo Nordisk (NVO) has a beta rating of 0.15. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.